Request a copy

Full Text

• Reginster JY. La place des bisphosphonates dans le traitement de l'ostéoporose. La lettre du Rhumatologue 1996 ; 222 : 3-7.
• Reginster JY. Ostéoporose postménopausique, Traitement prophylactique. Paris : Masson, 1993.
• Russell RGG, Fleisch H. Inorganic pyrophosphate and pyrophosphatases in calcification and calcium homeostasis. Clin Orthop 1970 ; 69 : 101-7.
• Reginster JY. Les bisphosphonates. Revue Médicale de Liège 1996 ; 51 : 120-2.
• Fleisch H. Bisphosphonates in bone disease, From the laboratory to the patient. Londres : The Parthenon Publishing Group, 1995.
• Heaney RP, Saville PD. Etidronate disodium in postmenopausal osteoporosis. Clin Pharm Therap 1976 ; 20 : 593-604.
• Storm T, Thamsborg G, Steinich T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990 ; 323 : 1265-71.
• Watts NB, Harris ST, Genant HK, et al. intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990 ; 323 : 73-9.
• Pacifici R, Mac Murty C, Vered I, et al. Coherence therapy does not prevent axial bone loss in osteoporotic women : A preliminary comparative study. J Clin Endocrinol Metab 1988 ; 66 : 747-53.
• Harris ST, Watts NB, Jackson RD, et al. Four-year of intermittent cyclic etidronate treatment of postmenopausal osteoporosis : Three years of blinded therapy followed by one year of open therapy. Am J Med 1993 ; 95 : 557-67.
• Axelrod DW, Teitelbaum SL. Results of long-term cyclical etidronate therapy : Bone histomorphometry and clinical corelates. J Bone Miner Res 1994 ; 9 (Suppl. 1) : 136S.
• Storm T, Thamsborg G, Kollerup G, Sorensen HA. Five years of intermittent cyclical etidronate therapy increases bone mass and reduces vertebral fracture rates in postmenopausal osreoporosis. Bone Miner 1992 ; 17 (Suppl. 1) : 24S.
• Valkema R, Vismans FJE, Papapoulos SE. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner 1989 ; 5 : 183-92.
• Reid IR, Wattie DJ, Evans MC, et al. Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 1994 ; 79 : 1595-9.
• Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate : An unrecognized problem in gastrointestinal tolerability. Osteoporosis Int 1994 ; 4 : 320-2.
• Devogelaer JP, Esselinckx W, Nagant de Deuxchaisnes CA. A randomized, controlled trial of APD (disodium pamidronate) given intravenously with and without sodium fluoride in involutional osteoporosis. J Bone Miner Res 1990 : 5(Suppl. 2) : 252S.
• Toolan BC, Shea M, Myers ER, et al. Effects of 4-amino-I-hydroxybutylidene bisphosphonate on bone biomecanics in rats. J Bone Miner Res 1992 ; 7 : 1399-406.
• Balena R, Toolan BC, Shea M, et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 1993 ; 92 : 2577-86.
• Harris ST, Gertz BJ, Genant HK, et al. The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 1993 ; 76 : 1399-406.
• Garnero P, Weichung J, Shih J, et al. Comparison of new chemical markers of bone turnover in late postmenopausal osteoporotic wo-men in response to alendronate treatment. J Clin Endocrinol Metab 1994 ; 79 : 1693-700.
• Downs R, Baker M, Bell N et al. Three-year treatment of osteoporosis in postmenopausal women with oral alendronate : Effects on bone mass and turnover, and safety. J Bone Miner Res 1995 ; 10(Suppl. 1) : 139S.
• Devogelaer JP, Broll H, Correa-Rotter R, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip and total body over 3 years in postmenopausal women with osteoporosis. Bone 1996 ; 18 : 141-50.
• Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal women. N Engl J Med 1995 ; 333 : 1437-43.
• Black DM, Cummings SR, Thompson D. The effect of alendronate on rates of vertebral and non-vertebral fractures in women with vertebral fractures : Preliminary results of the fracture intervention trial Osteoporis Int 1996 ; 6 (Suppl. 1) : 94S.
• Reginster JY, Compston JE, Jones EA, et al. Recommendations for the registration of new chemical entities used in the prevention and treatment of osteoporosis. Calcif Tissue Int 1995 ; 57 : 247-50.
• Mühlbauer RC, Bauss F, Schenk R, et al. Ibandronate, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991 ; 6 : 1003-11.
• Thiebaud D, Kriegbaum H, Huss M, et al. Intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Osteoporosis Int 1996 ; 6 (Suppl. 1) : 94S.
• Ravn P, Clemmesen B, Riis J, et al. The effect on bone mass and bone markers of different doses of ibandronate - a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis. A 1-year, randomized, double-blind, placebo controlled dose-finding study. Osteoporosis Int 1996 ; 6 (Suppl. 1) : 301S.
• Amman P, Rizzoli R, Caverzasio J. Effects of the bisphosphonate tiludronate on bone resorption, calcium balance and bone mineral density. J Bone Miner Res 1993 ; 8 : 1491-8.
• Geusens P, Nijs J, van Der Perrel C, et al. Longitudinal effects of tiludronate on bone mineral density, resonant frequency, and strength in monkeys. J Bone Miner Res 1992 ; 7 : 599-609.
• Chastagnier D, Barbier A, Vernejoul MC, et al. Effects of two bisphosphonates (tiludronate and etidronate) on bone healing. J Bone Miner Res 1993 ; 8 (Suppl. 1) : 236S.
• D Roux C, Gennari C, Farrerons J, et al. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in Paget's disease of bone. Arthritis Rheum 1995 ; 38 : 851-8.
• Reginster JY, Lecort MP, Deroisy R, at al. Prevention of postmenopausal bone loss by tiludronate. Lancet 1989 ; 2 : 1469-71.
• Reginster JY. Oral tiludronate : Pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis. Bone 1992 ; 13 : 351-4.
• Roux C, Deroisy R, Basse-Cathalinat B, et al. Prevention of early postmenopausal bone loss with oral tiludronate. Osteoporosis Int 1996 ; 6 (Suppl. 1) : 249S.
• Wronski TJ, Yen CF, Scott KS. Estrogen and diphosphonate treatment provide long-term protection against osteopenia in ovariectomized rats. J Bone Miner Res 1991 ; 6 : 387-94.
• Smith PN, Eastman DF, Shea M, et al. Biochemical properties of bone from dog following 2 years treatment with high dose risedronate. J Bone Miner Res 1995 ; 10 (Suppl. 1) : 352S.
• Mortensen L, Bekker P, Van den Ouweland, et al. Prevention of early postmenopausal bone loss by risedronate : A two-year study. 1 Bone Miner Res 1995 ; 10 (Supp. 1) : 352S.
• Delmas PD, Hardouin C, Confavreux E, et al. Intermittent risedronate prevents bone loss in women with artificial menopause induced by chemotherapy of breast cancer. J Bone Miner Res 1995 ; 10 (Suppl. 1) : 200S.
• Smith J, Shoukri K, Trahiotis M, et al. Bone marker changes in risedronate-treated postmenopausal women. J Bone Miner Res 1995 ; 10 (Suppl. 1) : 351S.
• Langdahl B, Eriksen EF, Mortensen L, et al. Histomorphometry from a three-year risedronate bone loss prevention study. J Bone Miner Res 1995 ; 10(Suppl. 1) : 199S.
• Zegels B, Balena R, Eastell R, et al. Effect of risedronate on collagen cross links in postmenopausal women. J Bone Miner Res 1995 ; 10(Suppl. 1) : 455S.
• Taquet AN, Clemmensen B, Zegels B, et al.